𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters

✍ Scribed by Yan Wang; Ming-Yi Xu; Rui-Dan Zheng; Jian-Chun Xian; Hong-Tao Xu; Jun-Ping Shi; Shi-Bo Li; Ying Qu; Yu-Wei Dong; Lun-Gen Lu

Book ID
117966655
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
344 KB
Volume
43
Category
Article
ISSN
1386-6346

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60